Zhejiang Hisun Pharma acquired China rights for a novel flu treatment from Japan’s Fujifilm. Hisun will develop, manufacture and market favipiravir in China. In return, Fujifilm will receive a lump-sum payment and royalties on sales, neither of which was disclosed. Two years ago, favipiravir was approved for use in Japan. It is thought to have efficacy against avian flu strains and Ebola, and could become an important drug should either one reach pandemic proportions.
